Topic
Oncology outcomes research, explained
12 open-access oncology outcomes studies, each with a flashcard deck and a quiz.
- miR-122 exosomes from fat stem cells sensitize HCC models to chemo
Adipose MSC exosomes loaded with miR-122 delivered the microRNA into HepG2 cells, downregulated CCNG1/ADAM10/IGF1R, and increased chemosensitivity in vitro and in xenografts combined with agents such as sorafenib.
- A 22-gene classifier flags early metastasis after prostatectomy
In Mayo radical-prostatectomy men, a 22-marker genomic classifier from primary-tumour expression predicted early clinical metastasis after PSA rise better than clinical variables (validation AUC 0.75).
- HDAC2 IHC tracks shorter PSA relapse in prostate cancer
In 192 prostate carcinomas, class I HDACs were often strongly expressed; HDAC2 independently predicted shorter PSA relapse and linked to dedifferentiation/proliferation.
- Five integrated genomic subgroups track prostate-cancer relapse risk
Across 259 men (482 samples), integrating copy-number and expression data defined five subgroups on 100 genes that predicted biochemical relapse in discovery, validation, and a third long-follow-up cohort.
- Higher tumour EZH2 tracks portal-vein invasion in HCC
In 66 resected HCC tumours, EZH2 mRNA was higher than in paired nontumour liver and high expression associated with portal-vein invasion (79% vs 39%), without a significant disease-free survival difference.
- DNA methylation signatures separate HCC from nearby liver
Promoter methylation arrays in 30 HCC tumours vs surrounding tissue produced a validated signature that distinguished HCC from adjacent liver (independent of major risk factors), with other methylation panels tracking risk factors, progression, and survival after therapy.
- Marital status and cancer survival trends
Among Norwegian cancer patients, never-married people—especially older men—showed growing excess mortality versus married peers over decades.
- ANXA1 in breast cancer prognosis
ANXA1-positive breast tumors clustered with poor-prognosis features (high grade, basal/TN, BRCA1/2) and worse outcomes in some high-risk subgroups such as HER2+.
- How big is the ovarian cancer burden in China, and where is it heading?
GBD 2019 estimates show China’s ovarian cancer prevalence/incidence/mortality ASRs rose sharply since 1990, with ~196k cases in 2019 and projected faster growth than the global average to 2030.
- Does socioeconomic status change cancer survival?
In Norwegian women, lower education and income predicted worse cancer survival until stage and smoking were accounted for.
- Can CHK1 blockade help BRCA-wild-type resistant ovarian cancer?
In 49 heavily pretreated BRCAwt platinum-resistant HGSOC patients, prexasertib yielded ~29–33% ORR with manageable but frequent neutropenia before early trial stop.
- Propofol vs sevoflurane and breast cancer survival
In the CAN randomised trial, five-year overall survival after primary breast cancer surgery was essentially the same with propofol or sevoflurane maintenance anaesthesia.